Total Payments
$90,918
2024 Payments
$1,532
Companies
39
Transactions
1,013
Medicare Patients
6,058
Medicare Billing
$9.0M
Payment Breakdown by Category
Other$59,456 (65.4%)
Food & Beverage$16,980 (18.7%)
Travel$9,150 (10.1%)
Consulting$5,126 (5.6%)
Education$206.18 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,456 | 35 | 65.4% |
| Food and Beverage | $16,980 | 934 | 18.7% |
| Travel and Lodging | $9,150 | 29 | 10.1% |
| Consulting Fee | $5,126 | 3 | 5.6% |
| Education | $206.18 | 12 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $36,880 | 94 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19,659 | 137 | $0 (2024) |
| ABBVIE INC. | $14,294 | 64 | $0 (2024) |
| Amgen Inc. | $10,448 | 187 | $0 (2024) |
| Janssen Biotech, Inc. | $2,035 | 85 | $0 (2024) |
| UCB, Inc. | $1,897 | 111 | $0 (2024) |
| PFIZER INC. | $1,080 | 99 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $513.25 | 40 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $466.61 | 15 | $0 (2019) |
| GlaxoSmithKline, LLC. | $310.28 | 23 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,532 | 77 | Amgen Inc. ($320.91) |
| 2023 | $1,607 | 85 | Amgen Inc. ($424.13) |
| 2022 | $1,603 | 96 | UCB, Inc. ($340.11) |
| 2021 | $4,085 | 123 | Amgen Inc. ($2,079) |
| 2020 | $5,423 | 79 | Amgen Inc. ($4,512) |
| 2019 | $26,834 | 202 | Celgene Corporation ($19,019) |
| 2018 | $17,162 | 160 | AbbVie, Inc. ($7,620) |
| 2017 | $32,672 | 191 | Celgene Corporation ($12,977) |
All Payment Transactions
1,013 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $32.26 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $8.79 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.66 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Dermatology | ||||||
| 11/11/2024 | Azurity Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.64 | General |
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Immunology | ||||||
| 10/08/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/08/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Inflammation | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Dermatology | ||||||
| 10/02/2024 | Bioventus LLC | SUPARTZ FX SODIUM HYALURONATE (Device) | Food and Beverage | In-kind items and services | $37.80 | General |
| Category: DEVICES | ||||||
| 10/01/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $10.58 | General |
| Category: Inflammation | ||||||
| 09/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Dermatology | ||||||
| 09/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/17/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $12.34 | General |
| Category: Inflammation | ||||||
| 09/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Immunology | ||||||
| 09/10/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: Immunology | ||||||
| 09/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Dermatology | ||||||
| 08/28/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,237 | 137,907 | $5.2M | $1.7M |
| 2022 | 17 | 1,465 | 161,711 | $6.1M | $2.2M |
| 2021 | 21 | 1,667 | 162,240 | $6.3M | $2.6M |
| 2020 | 21 | 1,689 | 148,382 | $5.9M | $2.6M |
Total Patients
6,058
Total Services
610,240
Medicare Billing
$9.0M
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 61 | 57,110 | $2.6M | $601,403 | 23.4% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 22 | 12,500 | $750,000 | $414,068 | 55.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 13 | 53,600 | $696,800 | $210,281 | 30.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 27 | 5,810 | $581,000 | $152,946 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 441 | 1,638 | $245,700 | $138,695 | 56.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 37 | 3,900 | $84,500 | $66,077 | 78.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 112 | 682 | $170,500 | $57,399 | 33.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 266 | $26,600 | $13,646 | 51.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 74 | 74 | $22,200 | $11,083 | 49.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 103 | 144 | $18,720 | $6,672 | 35.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 28 | 322 | $24,225 | $6,236 | 25.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 111 | 673 | $16,825 | $5,653 | 33.6% |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | Office | 2023 | 12 | 780 | $15,600 | $3,858 | 24.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 25 | $2,750 | $1,619 | 58.9% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 113 | 304 | $16,610 | $1,535 | 9.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 37 | 65 | $3,250 | $630.60 | 19.4% |
| 20550 | Injection into tendon or ligament | Office | 2023 | 12 | 14 | $1,680 | $604.24 | 36.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 77 | 67,950 | $3.1M | $803,406 | 26.3% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 24 | 15,300 | $918,000 | $528,507 | 57.6% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 16 | 61,200 | $734,400 | $277,481 | 37.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 29 | 6,206 | $620,600 | $177,664 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 489 | 1,913 | $286,950 | $164,504 | 57.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 41 | 4,560 | $98,800 | $77,181 | 78.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 126 | 788 | $197,000 | $71,150 | 36.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 16 | 304 | $30,400 | $16,070 | 52.9% |
About Dr. Amir Agha, MD
Dr. Amir Agha, MD is a Rheumatology healthcare provider based in Decatur, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730144114.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amir Agha, MD has received a total of $90,918 in payments from pharmaceutical and medical device companies, with $1,532 received in 2024. These payments were reported across 1,013 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($59,456).
As a Medicare-enrolled provider, Agha has provided services to 6,058 Medicare beneficiaries, totaling 610,240 services with total Medicare billing of $9.0M. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Decatur, GA
- Active Since 04/19/2006
- Last Updated 02/02/2026
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1730144114
Products in Payments
- Otezla (Drug) $42,241
- COSENTYX (Biological) $19,428
- Humira (Biological) $10,186
- Otezla (Biological) $2,150
- Enbrel (Biological) $2,041
- Cimzia (Drug) $1,853
- TREMFYA (Drug) $913.55
- XELJANZ (Drug) $871.28
- STELARA (Biological) $799.76
- ORENCIA (Biological) $510.27
- SIMPONI ARIA (Biological) $432.46
- ACTHAR (Biological) $426.66
- RINVOQ (Biological) $360.61
- KEVZARA SARILUMAB INJECTION (Biological) $329.27
- BENLYSTA (Biological) $310.28
- TALTZ (Drug) $271.48
- SAPHNELO (Biological) $232.73
- COSENTYX (Drug) $231.25
- KEVZARA (Biological) $183.98
- PURIFIED CORTROPHIN GEL (Drug) $164.88
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Decatur
Jefrey Lieberman, Md, MD
Rheumatology — Payments: $353,561
Rheumatology $353,561
Arshad Mustafa, M.d, M.D
Rheumatology — Payments: $13,092
Rheumatology $13,092
Dr. Gary Botstein, M.d, M.D
Rheumatology — Payments: $7,376
Rheumatology $7,376
Nehemiah Tan, M.d, M.D
Rheumatology — Payments: $6,024
Rheumatology $6,024
Emily Peninger, Md, MD
Rheumatology — Payments: $3,320
Rheumatology $3,320
Manoj Kohli, Md, MD
Rheumatology — Payments: $1,351
Rheumatology $1,351